C
Cornelis M. van Tilburg
Researcher at German Cancer Research Center
Publications - 73
Citations - 2689
Cornelis M. van Tilburg is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 41 publications receiving 1503 citations. Previous affiliations of Cornelis M. van Tilburg include Heidelberg University & University Hospital Heidelberg.
Papers
More filters
Journal ArticleDOI
The landscape of genomic alterations across childhood cancers
Susanne Gröbner,Barbara C. Worst,Joachim Weischenfeldt,Joachim Weischenfeldt,Ivo Buchhalter,Kortine Kleinheinz,Vasilisa A. Rudneva,Pascal Johann,Gnana Prakash Balasubramanian,Maia Segura-Wang,Sebastian Brabetz,Sebastian Bender,Barbara Hutter,Dominik Sturm,Elke Pfaff,Daniel Hübschmann,Gideon Zipprich,Michael Heinold,Michael Heinold,Jürgen Eils,Christian Lawerenz,Serap Erkek,Sander Lambo,Sebastian M. Waszak,Claudia Blattmann,Arndt Borkhardt,Arndt Borkhardt,Michaela Kuhlen,Michaela Kuhlen,Angelika Eggert,Angelika Eggert,Simone Fulda,Manfred Gessler,Jenny Wegert,Roland Kappler,Roland Kappler,Daniel Baumhoer,Stefan Burdach,Stefan Burdach,Renate Kirschner-Schwabe,Renate Kirschner-Schwabe,Udo Kontny,Andreas E. Kulozik,Andreas E. Kulozik,Dietmar R. Lohmann,Simone Hettmer,Cornelia Eckert,Cornelia Eckert,Stefan S. Bielack,Michaela Nathrath,Michaela Nathrath,Charlotte M. Niemeyer,Charlotte M. Niemeyer,Gunther Richter,Gunther Richter,Johannes H. Schulte,Johannes H. Schulte,Reiner Siebert,Frank Westermann,Jan J. Molenaar,Gilles Vassal,Hendrik Witt,Peter Lichter,Ursula Weber,Roland Eils,Roland Eils,Andrey Korshunov,Olaf Witt,Stefan Pfister,Guido Reifenberger,J Felsberg,Christof von Kalle,Manfred Schmidt,Cynthia Bartholomä,Michael Taylor,David T. W. Jones,Natalie Jäger,Korbel Jo,Adrian M. Stütz,Tobias Rausch,Bernhard Radlwimmer,Marie-Laure Yaspo,Hans Lehrach,Hans-Jörg Warnatz,Pablo Landgraf,Benedikt Brors,Marc Zapatka,Marc Zapatka,Susanne Wagner,Susanne Wagner,Andrea Haake,Julia Richter,Gesine Richter,Gesine Richter,Chris Lawerenz,Jules Kerssemakers,Christina Jaeger-Schmidt,Ingrid Scholz,Anke K. Bergmann,Christoph Borst,Birgit Burkhardt,Alexander Claviez,Martin Dreyling,Martin Dreyling,Sonja Eberth,Hermann Einsele,Norbert Frickhofen,Siegfried Haas,Martin-Leo Hansmann,Dennis Karsch,Michael Kneba,Jasmin Lisfeld,Luisa Mantovani-Löffler,Marius Rohde,German Ott,Christina Stadler,Peter Staib,Stephan Stilgenbauer,Lorenz Trümper,Thorsten Zenz,Dieter Kube,Ralf Küppers,Marc A. Weniger,Michael Hummel,Wolfram Klapper,Ulrike Kostezka,Dido Lenze,Peter Möller,Andreas Rosenwald,Monika Szczepanowski,Ole Ammerpohl,Sietse M. Aukema,Vera Binder,Jessica I. Hoell,Ellen Leich,Cristina López,Inga Nagel,Jordan Pischimariov,Philip Rosenstiel,Markus Schilhabel,Stefan Schreiber,Inga Vater,Rabea Wagener,Stephan H. Bernhart,Hans Binder,Gero Doose,Steve Hoffmann,Lydia Hopp,Helene Kretzmer,Markus Kreuz,David Langenberger,Markus Loeffler,Maciej Rosolowski,Matthias Schlesner,Peter F. Stadler,Stephanie Sungalee,Christian P. Kratz,Cornelis M. van Tilburg,Christof M. Kramm,Gudrun Fleischhack,Gudrun Fleischhack,Uta Dirksen,Stefan Rutkowski,Michael C. Frühwald,Katja von Hoff,Stephan Wolf,Thomas Klingebiel,Thomas Klingebiel,Ewa Koscielniak,Jan Koster,Adam C. Resnick,Jinghui Zhang,Yanling Liu,Xin Zhou,Angela J. Waanders,Danny A. Zwijnenburg,Pichai Raman,Ursula D. Weber,Paul A. Northcott,Kristian W. Pajtler,Marcel Kool,Rosario M. Piro,Jan O. Korbel,David T.W. Jones,Lukas Chavez,Stefan M. Pfister +185 more
TL;DR: The data suggest that 7–8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.
Journal ArticleDOI
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong,Steven G. DuBois,Shivaani Kummar,Anna F. Farago,Catherine M. Albert,Kristoffer Staal Rohrberg,Cornelis M. van Tilburg,Cornelis M. van Tilburg,Ramamoorthy Nagasubramanian,Jordan Berlin,Noah Federman,Leo Mascarenhas,Birgit Geoerger,Afshin Dowlati,Alberto S. Pappo,Stefan S. Bielack,François Doz,Ray McDermott,Jyoti D. Patel,Russell J. Schilder,Makoto Tahara,Stefan M. Pfister,Stefan M. Pfister,Olaf Witt,Olaf Witt,Marc Ladanyi,Erin R. Rudzinski,Shivani Nanda,Barrett H. Childs,Theodore W. Laetsch,David M. Hyman,David M. Hyman,Alexander Drilon,Alexander Drilon +33 more
TL;DR: These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active and indicate that long-term administration of larot rectinib are feasible.
Journal ArticleDOI
Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study
Barbara C. Worst,Barbara C. Worst,Cornelis M. van Tilburg,Gnana Prakash Balasubramanian,Petra Fiesel,Petra Fiesel,Ruth Witt,Angelika Freitag,Miream Boudalil,Miream Boudalil,Christopher Previti,Stephan Wolf,Sabine Schmidt,Sasithorn Chotewutmontri,Melanie Bewerunge-Hudler,Matthias Schick,Matthias Schlesner,Barbara Hutter,Lenka A. Taylor,Tobias Borst,Christian Sutter,Claus R. Bartram,Till Milde,Till Milde,Elke Pfaff,Elke Pfaff,Andreas E. Kulozik,Arend von Stackelberg,Roland Meisel,Arndt Borkhardt,Dirk Reinhardt,Jan-Henning Klusmann,Gudrun Fleischhack,Stephan Tippelt,Uta Dirksen,Heribert Jürgens,Christof M. Kramm,André O. von Bueren,Frank Westermann,Matthias Fischer,Matthias Fischer,Birgit Burkhardt,Wilhelm Wößmann,Michaela Nathrath,Stefan S. Bielack,Michael C. Frühwald,Simone Fulda,Thomas Klingebiel,Ewa Koscielniak,Matthias Schwab,Matthias Schwab,Roman Tremmel,Roman Tremmel,Pablo Hernáiz Driever,Johannes H. Schulte,Benedikt Brors,Andreas von Deimling,Andreas von Deimling,Peter Lichter,Angelika Eggert,David Capper,David Capper,Stefan M. Pfister,Stefan M. Pfister,David T.W. Jones,Olaf Witt,Olaf Witt +66 more
TL;DR: This study demonstrates the feasibility of comprehensive, real-time molecular profiling for high-risk paediatric cancer patients and expands upon previous personalised oncology endeavors, and presents a model with considerable interest and practical relevance in the burgeoning era of personalised medicine.
Journal ArticleDOI
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
Sebastian Bender,Sebastian Bender,Jan Gronych,Hans-Jörg Warnatz,Barbara Hutter,Susanne Gröbner,Marina Ryzhova,Elke Pfaff,Elke Pfaff,Volker Hovestadt,Florian Weinberg,Sebastian Halbach,Marcel Kool,Paul A. Northcott,Dominik Sturm,Dominik Sturm,Lynn Bjerke,Thomas Zichner,Adrian M. Stütz,Kathrin Schramm,Bingding Huang,Ivo Buchhalter,Michael Heinold,Thomas Risch,Barbara C. Worst,Barbara C. Worst,Cornelis M. van Tilburg,Cornelis M. van Tilburg,Ursula D. Weber,Marc Zapatka,Benjamin Raeder,David Milford,Sabine Heiland,Christof von Kalle,Christopher Previti,Chris Lawerenz,Andreas E. Kulozik,Andreas Unterberg,Olaf Witt,Andreas von Deimling,David Capper,David Capper,Nathalene Truffaux,Nathalene Truffaux,Jacques Grill,Jacques Grill,Nada Jabado,Astrid Sehested,David Sumerauer,Dorra H'mida-Ben Brahim,Saoussen Trabelsi,Ho Keung Ng,David Zagzag,Jeffrey C. Allen,Matthias A. Karajannis,Nicholas G. Gottardo,Chris Jones,Jan O. Korbel,Sabine Schmidt,Stephan Wolf,Guido Reifenberger,Jörg Felsberg,Benedikt Brors,Christel Herold-Mende,Hans Lehrach,Tilman Brummer,Andrey Korshunov,Roland Eils,Marie-Laure Yaspo,Stefan M. Pfister,Peter Lichter,David T.W. Jones +71 more
TL;DR: An integrative genetic analysis of 53 pediatric glioblastomas and five in vitro model systems identified previously unidentified gene fusions involving the MET oncogene, which activated mitogen-activated protein kinase (MAPK) signaling and induced aggressive glial tumors in vivo.
Journal ArticleDOI
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study
Afshin Saffari,Ines Brösse,Adelheid Wiemer-Kruel,Bernd Wilken,Paula Kreuzaler,Andreas Hahn,Matthias K. Bernhard,Cornelis M. van Tilburg,Cornelis M. van Tilburg,Georg F. Hoffmann,Matthias Gorenflo,Sven Hethey,O. Kaiser,Stefan Kölker,Robert Wagner,Olaf Witt,Olaf Witt,Andreas Merkenschlager,Andreas Möckel,Timo Roser,Jan-Ulrich Schlump,Antje Serfling,Juliane Spiegler,Till Milde,Till Milde,Andreas Ziegler,Steffen Syrbe +26 more
TL;DR: This retrospective multicenter study demonstrates that mTOR inhibitor treatment with everolimus is safe in TSC patients under the age of 2 years and shows beneficial effects on cardiac manifestations, SEGA size and early epilepsy.